Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Sorawel Sorafenib Tablets 200 mg
Sorawel is a targeted cancer therapy designed to inhibit tumor growth and angiogenesis in patients with advanced kidney, liver, and thyroid cancers. It contains Sorafenib 200 mg, a multikinase inhibitor that blocks cancer cell proliferation and blood vessel formation.
Uses of Sorawel Sorafenib Tablets 200 mg
Treatment of advanced hepatocellular carcinoma (HCC)
Management of advanced renal cell carcinoma (RCC)
Therapy for radioactive iodine-resistant differentiated thyroid carcinoma (DTC)
Benefits of Sorawel Sorafenib Tablets 200 mg
Inhibits tumor growth and progression
Reduces blood supply to cancer cells, limiting their spread
Oral formulation for convenient administration
Clinically proven to improve survival rates in advanced cancer patients
Mechanism of Action of Sorawel Sorafenib Tablets 200 mg
Sorafenib targets multiple kinases, including VEGFR, PDGFR, and RAF kinases, to block tumor growth and angiogenesis. By inhibiting these pathways, it slows cancer progression and reduces tumor blood vessel formation, effectively starving cancer cells of essential nutrients.